Pro-Pharmaceuticals’ patent-pending products are built upon a Glycoscience-based technology platform that utilizes a compatible, immuno-beneficial drug delivery vehicle to transport a standard chemotherapy directly into the cancer cells, without harming healthy cells.

Our technical objective is to employ the sugar-specific receptors sites found on the cancer cell surface to facilitate the delivery of well known FDA approved chemotherapy agents, whereby increasing their efficacy and reducing their toxicity.

Pro-Pharmaceuticals’ principal solution is to develop upgraded formulations for existing anti-cancer therapies. Our program is “risk contained”, focusing upon proven drugs for which there is already a great deal of data on record of therapeutic efficacy and toxicity, along with an accumulated knowledge regarding their limitations.